RxDoctor Payments Data

Dottie Ann Sazon, MD

Pulmonary Disease · National City, CANPI 1033222708

Payments from drug & device makers

$11,368in general payments, 2019–2025

Across 139 payments — averaging $81.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • AstraZeneca$3K
  • Sunovion Pharmaceuticals Inc.$2K
  • Boehringer Ingelheim$372
  • Harmony Biosciences LLC$240
  • Actelion Pharmaceuticals US, Inc.$218
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$7,55066%
  • Travel & lodging$731%
  • Food & beverage$3,54331%
  • Education$2022%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,368 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$208,720
Medicare patients
422
Services billed
1,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter385$426,922
TezspireTezepelumab-Ekko25$145,223
Breo ElliptaFluticasone/Vilanterol73$45,499
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$27,112
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,238
Spiriva RespimatTiotropium Bromide11$11,647
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,304
BreynaBudesonide/Formoterol Fumarate18$6,340
Varenicline Tartrate28$5,602
Fluticasone Propionate205$4,880
Albuterol Sulfate HfaAlbuterol Sulfate168$4,720
Roflumilast50$4,335
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,828
Mometasone Furoate14$3,190
Montelukast Sodium190$2,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$4,082$479,726470 claims
AstraZenecaTezspire, Breztri Aerosphere$3,011$157,46136 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$372$38,75956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in National City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →